Immunogenicity of prostate cancer is augmented by BET bromodomain inhibition
dc.contributor.author | Mao, Wendy | |
dc.contributor.author | Ghasemzadeh, Ali | |
dc.contributor.author | Freeman, Zachary T. | |
dc.contributor.author | Obradovic, Aleksandar | |
dc.contributor.author | Chaimowitz, Matthew G. | |
dc.contributor.author | Nirschl, Thomas R. | |
dc.contributor.author | McKiernan, Emily | |
dc.contributor.author | Yegnasubramanian, Srinivasan | |
dc.contributor.author | Drake, Charles G. | |
dc.date.accessioned | 2019-11-26T13:54:44Z | |
dc.date.available | 2019-11-26T13:54:44Z | |
dc.date.issued | 2019-10-25 | |
dc.identifier.citation | Journal for ImmunoTherapy of Cancer. 2019 Oct 25;7(1):277 | |
dc.identifier.uri | https://doi.org/10.1186/s40425-019-0758-y | |
dc.identifier.uri | https://hdl.handle.net/2027.42/152251 | |
dc.description.abstract | Abstract Background Prostate cancer responds poorly to current immunotherapies. Epigenetic therapies such as BET Bromodomain inhibition can change the transcriptome of tumor cells, possibly making them more immunogenic and thus susceptible to immune targeting. Methods We characterized the effects of BET bromodomain inhibition using JQ1 on PD-L1 and HLA-ABC expression in two human prostate cell lines, DU145 and PC3. RNA-Seq was performed to assess changes on a genome-wide level. A cytotoxic T cell killing assay was performed in MC38-OVA cells treated with JQ1 to demonstrate increased immunogenicity. In vivo experiments in the Myc-Cap model were conducted to show the effects of JQ1 administration in concert with anti-CTLA-4 checkpoint blockade. Results Here, we show that targeting BET bromodomains using the small molecule inhibitor JQ1 decreased PD-L1 expression and mitigated tumor progression in prostate cancer models. Mechanistically, BET bromodomain inhibition increased MHC I expression and increased the immunogenicity of tumor cells. Transcriptional profiling showed that BET bromodomain inhibition regulates distinct networks of antigen processing and immune checkpoint molecules. In murine models, treatment with JQ1 was additive with anti-CTLA-4 immunotherapy, resulting in an increased CD8/Treg ratio. Conclusions BET Bromodomain inhibition can mediate changes in expression at a genome wide level in prostate cancer cells, resulting in an increased susceptibility to CD8 T cell targeting. These data suggest that combining BET bromodomain inhibition with immune checkpoint blockade may have clinical activity in prostate cancer patients. | |
dc.title | Immunogenicity of prostate cancer is augmented by BET bromodomain inhibition | |
dc.type | Article | en_US |
dc.description.bitstreamurl | https://deepblue.lib.umich.edu/bitstream/2027.42/152251/1/40425_2019_Article_758.pdf | |
dc.language.rfc3066 | en | |
dc.rights.holder | The Author(s). | |
dc.date.updated | 2019-11-26T13:54:45Z | |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.